Advertisement

American Journal of Clinical Dermatology

, Volume 14, Issue 5, pp 351–358 | Cite as

The Management of Acne Vulgaris in Pregnancy

  • Fiona M. Meredith
  • Anthony D. OrmerodEmail author
Therapy in Practice

Abstract

Acne vulgaris is a common condition in adolescence and also for many women of childbearing age. The management of acne in pregnancy is complicated by the lack of clinical studies and pharmacokinetic data in this patient population and safety concerns regarding retinoid use in pregnancy. Of primary concern to both patients and clinicians is the safety profile of medications used during pregnancy. This review seeks to clarify what management options are available to treat acne during pregnancy and what data are available to guide decision making. Topical treatments are considered the safest option during pregnancy. They have the best safety profile and minimize the levels of systemic absorption, and therefore the least risk of fetal exposure. If these are applied properly with a strong emphasis on adherence, excellent results can be achieved.

Keywords

Acne Isotretinoin Benzoyl Peroxide Azelaic Acid Tazarotene 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

Both authors have no relevant conflicts of interest. FMM researched and drafted the initial document, which was then reviewed and edited by ADO.

References:

  1. 1.
    Smithard A, Glazebrook C, Williams HC. Acne prevalence, knowledge about acne and psychological morbidity in mid-adolescence: a community-based study. Br J Dermatol. 2001;145:274–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Bhate K, Williams HC. Epidemiology of acne vulgaris. Br J Dermatol. 2013;168:474–85.PubMedCrossRefGoogle Scholar
  3. 3.
    Williams C, Layton AM. Persistent acne in women: implications for the patient and for therapy. Am J Clin Dermatol. 2006;7(5):281–90.PubMedCrossRefGoogle Scholar
  4. 4.
    Shafer T, Nienhaus A, Vieluf D, et al. Epidemiology of acne in the general population: the risk of smoking. Br J Dermatol. 2001;145:100–4.CrossRefGoogle Scholar
  5. 5.
    Burton JL, Cunliffe WJ, Stafford I, et al. The prevalence of acne vulgaris in adolescence. Br J Dermatol. 1971;85:119–26.PubMedCrossRefGoogle Scholar
  6. 6.
    US Food and Drug Administration. List of pregnancy exposure registries [online]. http://www.fda.gov/scienceresearch/specialtopics/womenshealthresearch/ucm134848.htm (Accessed 12 Dec 2012).
  7. 7.
    FDA Consumer Health Information. Pregnant women to benefit from better information [online]. http://www.fda.gov/downloads/ForConsumers/ConsumerUpdates/UCM143746.pdf (Accessed 12 Dec 2012).
  8. 8.
    Strauss JS, Krowchuk DP, Leyden JJ, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007;56:651–63.PubMedCrossRefGoogle Scholar
  9. 9.
    Nast A, Dréno B, Bettoli V, et al. European evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol. 2012;26:1–29.PubMedCrossRefGoogle Scholar
  10. 10.
    Elling SV, Powell FC. Physiological changes in the skin during pregnancy. Clin Dermatol. 1997;15:35–43.PubMedCrossRefGoogle Scholar
  11. 11.
    Burton JL, Cunliffe WJ, Millar DG, Shuster S. Effect of pregnancy on sebum excretion. BMJ. 1970;2:769–71.PubMedCrossRefGoogle Scholar
  12. 12.
    Muzaffar F, Hussain I, Haroon TS. Physiologic skin changes during pregnancy: a study of 140 cases. Int J Dermatol. 1998;37:429–31.PubMedCrossRefGoogle Scholar
  13. 13.
    Dawes M, Chowienczyk PJ. Drugs in pregnancy: pharmacokinetics in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2001;15:819–26.PubMedCrossRefGoogle Scholar
  14. 14.
    Loebstein R, Lalkin A, Koren G. Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet. 1997;33:328–43.PubMedCrossRefGoogle Scholar
  15. 15.
    Boothby LA, Doering PL. FDA labeling system for drugs in pregnancy. Ann Pharmacother. 2001;35:1485–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Public Affairs Committee of the Teratology Society. Teratology Public Affairs Committee position paper: pregnancy labeling for prescription drugs: ten years later. Birth Defects Res Part A Clin Mol Teratol. 2007;79:627–30.CrossRefGoogle Scholar
  17. 17.
    Addis A, Sharabi S, Bonati M. Risk classification systems for drug use during pregnancy: are they a reliable source of information? Drug Saf. 2000;23(3):245–53.PubMedCrossRefGoogle Scholar
  18. 18.
    US Food and Drug administration. Pregnancy and lactation labeling [online]. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093307.htm (Accessed 12 Dec 2012).
  19. 19.
    MIMS USA drug information system [online]: http://www.mims.com/USA/Viewer/Html/PregDef.htm (Accessed 12 Dec 2012).
  20. 20.
    Tanghetti E. The evolution of benzoyl peroxide therapy. Cutis. 2008;82(5 Suppl.):5–11.PubMedGoogle Scholar
  21. 21.
    Yeung D, Nacht S, Bucks D, Maibach HI. Benzoyl peroxide: percutaneous penetration and metabolic disposition. II. Effect of concentration. J Am Acad Dermatol. 1983;9:920–4.PubMedCrossRefGoogle Scholar
  22. 22.
    Nacht S, Yeung D, Beasley JN, et al. Benzoyl peroxide: percutaneous penetration and metabolic disposition. J Am Acad Dermatol. 1981;4(1):31–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Camera G, Pregliasco P. Ear malformation in baby born to mother using tretinoin cream. Lancet. 1992;339:687.PubMedCrossRefGoogle Scholar
  24. 24.
    Lipson AH, Collins C, Webster W. Multiple congenital defects associated with maternal use of topical tretinoin. Lancet. 1993;341:1352–3.PubMedCrossRefGoogle Scholar
  25. 25.
    Selcen D, Seidman S, Nigro MA. Otocerebral anomalies associated with topical tretinoin use. Brain Dev. 2000;22:218–20.PubMedCrossRefGoogle Scholar
  26. 26.
    Navarre-Belhassen C, Blanchet P, Hillaire-Buys D, et al. Multiple congenital malformations associated with topical tretinoin. Ann Pharmacother. 1998;32:505–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Autret E, Berjot M, Jonville-Béra A-P, et al. Anophthalmia and agenesis of optic chiasma associated with adapalene gel in early pregnancy. Lancet. 1997;350:339.PubMedCrossRefGoogle Scholar
  28. 28.
    Organisation of Teratology Information specialists. Tretinoin (Retin-A®) and pregnancy [online]. http://www.otispregnancy.org/files/tretinoin.pdf (Accessed 12 Dec 2012).
  29. 29.
    Jick SS, Terris BZ, Jick H. First trimester topical tretinoin and congenital disorders. Lancet. 1993;341:1181–2.PubMedCrossRefGoogle Scholar
  30. 30.
    Panchaud P, Csajka C, Merlob P, et al. Pregnancy outcome following exposure to topical retinoids: a multicentre prospective study. J Clin Pharmacol. 2012;52:1844–51.PubMedCrossRefGoogle Scholar
  31. 31.
    Van Hoogdalem EJ. Transdermal absorption of topical anti-acne agents in man; review of clinical pharmacokinetic data. J Eur Acad Dermatol Venereol. 1998;11 Suppl. 1:S13–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Akhavan A, Bershad S. Topical acne drugs: review of clinical properties, systemic exposure and safety. Am J Clin Dermatol. 2003;4:473–92.PubMedCrossRefGoogle Scholar
  33. 33.
    Joint Formulary Committee. British National Formulary. 64th ed. London: BMJ Group and Pharmaceutical Press; 2012.Google Scholar
  34. 34.
    Frampton JE, Wagstaff AJ. Azelaic acid 15% gel in treatment of papulopustular rosacea. Am J Clin Dermatol. 2004;5:57–64.PubMedCrossRefGoogle Scholar
  35. 35.
    Täuber U, Weiss C, Matthes H. Percutaneous absorption of azelaic acid in humans. Exp Dermatol. 1992;1:176–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med. 1998;338:1128–37.PubMedCrossRefGoogle Scholar
  37. 37.
    Feldmann RJ, Maibach HI. Absorption of organic compounds through the skin in man. J Invest Dermatol. 1970;54:399–404.PubMedCrossRefGoogle Scholar
  38. 38.
    Dreno B, Bettoli V, Ochsendorf F, et al. European recommendations on the use of oral antibiotics for acne. Eur J Dermatol. 2004;14:391–9.PubMedGoogle Scholar
  39. 39.
    Harkaway KS, McGinley KJ, Foglia AN, et al. Antibiotic resistance patterns in coagulase-negative staphylococci after treatment with topical erythromycin, benzoyl peroxide, and combination therapy. Br J Dermatol. 1992;126:586–90.PubMedCrossRefGoogle Scholar
  40. 40.
    Hernandez S, Werler MM, Walker AM, et al. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med. 2000;343:1608–14.CrossRefGoogle Scholar
  41. 41.
    Hale EK, Pomeranz MK. Dermatological agents during pregnancy and lactation: an update and clinical review. Int J Dermatol. 2002;41:197–203.PubMedCrossRefGoogle Scholar
  42. 42.
    Cunliffe WJ, C’otterill JA, Williamson B. The effect of clindamycin in acne: a clinical and laboratory investigation. Br J Dermatol. 1972;87:37–41.PubMedCrossRefGoogle Scholar
  43. 43.
    Tan SG, Cunliffe WJ. The unwanted effects of clindamycin in acne. Br J Dermatol. 1976;94:313–5.PubMedCrossRefGoogle Scholar
  44. 44.
    Owens RC, Donskey CJ, Gayens RP, et al. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008;46(Suppl. 1):S19–31.PubMedCrossRefGoogle Scholar
  45. 45.
    Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008.Google Scholar
  46. 46.
    Romøren M, Lindbæk M, Nordeng H. Pregnancy outcome after gestational exposure to erythromycin: a population-based register study from Norway. Br J Clin Pharmacol. 2012;74:1053–62.PubMedCrossRefGoogle Scholar
  47. 47.
    Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: an update from the Global Alliance to improve outcomes in acne group. J Am Acad Dermatol. 2009;60(5 Suppl.):S1–50.PubMedCrossRefGoogle Scholar
  48. 48.
    Sweetman SC, et al. Martindale: the complete drug reference. 34th ed. London: Pharmaceutical Press; 2005.Google Scholar
  49. 49.
    Kus S, Yucelten D, Aytug A. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of acne vulgaris. Clin Exp Dermatol. 2004;30:215–20.CrossRefGoogle Scholar
  50. 50.
    UK Medicines and Healthcare products Regulatory Agency (MHRA) azithromycin UKPAR (UK Public Assessment Reports for medicines). http://www.mhra.gov.uk/home/groups/pl-a/documents/websiteresources/con023376.pdf (Accessed 4 July 2013).
  51. 51.
    Goodfellow A, Alaghband-Zadeh J, Carter G, et al. Oral spironolactone improves acne vulgaris and reduces sebum excretion. Br J Dermatol. 1984;111:209–14.PubMedCrossRefGoogle Scholar
  52. 52.
    Muhlemann MF, Carter GD, Cream JJ, Wise P. Oral spironolactone: an effective treatment for acne vulgaris in women. Br J Dermatol. 1986;115:227–32.PubMedCrossRefGoogle Scholar
  53. 53.
    Jaussan V, Lemarchand-Beraud T, Gomez F. Modifications of the gonadal function in the adult rat after fetal exposure to spironolactone. Biol Reprod. 1985;32:1051–61.PubMedCrossRefGoogle Scholar
  54. 54.
    Goodfield MJ, Cox NH, Bowser A, et al. Advice on the safe introduction and continued use of isotretinoin in acne in the U.K.: 2010. Br J Dermatol. 2010;162:1172–9.PubMedCrossRefGoogle Scholar
  55. 55.
    Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med. 1985;313:837–41.PubMedCrossRefGoogle Scholar
  56. 56.
    Dreno B, Blouin E. Acne, pregnant women and zinc salts: a literature review. Ann Dermatol Venereol. 2008;135(1):27–33.PubMedCrossRefGoogle Scholar
  57. 57.
    Du-Thanh A, Klugr N, Bensalleh H, Guillot B. Drug-induced acneiform eruption. Am J Clin Dermatol. 2011;12:233–45.PubMedCrossRefGoogle Scholar
  58. 58.
    Seukeran DC, Cunliffe WJ. The treatment of acne fulminans: a review of 25 cases. Br J Dermatol. 1999;141:307–9.PubMedCrossRefGoogle Scholar
  59. 59.
    Gur C, Diav-Citrin O, Shechtman S, et al. Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study. Reprod Toxicol. 2004;18:93–101.PubMedCrossRefGoogle Scholar
  60. 60.
    Committee on safety of medicines/medicines control agency. Systemic corticosteroids in pregnancy and lactation. Curr Probl. 1998;24:9. http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con2023392.pdf (Accessed 28 June 2013).
  61. 61.
    Ross EV. Optical treatments for acne. Dermatol Ther. 2005;18:253–66.PubMedCrossRefGoogle Scholar
  62. 62.
    Car J, Car M, Hamilton F, et al. Light therapies for acne (intervention protocol). Cochrane Database Syst Rev. 2009;(3):CD007917.Google Scholar
  63. 63.
    Sakamoto FH, Torezan L, Anderson R. Photodynamic therapy for acne vulgaris: a critical review from basics to clinical practice: part II. Understanding parameters for acne treatment with photodynamic therapy. J Am Acad Dermatol. 2010;63:195–211.PubMedCrossRefGoogle Scholar
  64. 64.
    Zeichner JA. Narrowband UV-B phototherapy for the treatment of acne vulgaris during pregnancy. Arch Dermatol. 2011;147:537–9.PubMedCrossRefGoogle Scholar
  65. 65.
    Cunliffe WJ, Holland DB, Clark SM, Stables GI. Comedogenesis: some new aetiological, clinical and therapeutic strategies. Br J Dermatol. 2000;142:1084–91.PubMedCrossRefGoogle Scholar
  66. 66.
    Zip C. A practical guide to dermatological drug use in pregnancy. Skin Ther Lett. 2006;11:1–4.Google Scholar
  67. 67.
    Crider KS, Cleves MA, Reefhuis J, et al. Antibacterial medication use during pregnancy and risk of birth defects. Arch Pediatr Adolesc Med. 2009;163(11):978–85.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.Department of DermatologyAberdeen Royal InfirmaryAberdeenUK
  2. 2.Division of Applied MedicineUniversity of AberdeenAberdeenUK

Personalised recommendations